https://www.cell.com/trends/biotechnology/fulltext/S0167-7799(26)00232-5
chatGPT(5.5 paid):
Summary
The paper is a short Forum article proposing “age engineering” or “ageneering”: deliberately manipulating the age-like state of cells, extracellular matrix, and engineered tissues in vitro. The motivation is that many tissue-engineered models, organoids, spheroids, and organs-on-chips use cells without considering whether they resemble young or old tissue, even though ageing changes genomic stability, epigenetics, metabolism, ECM composition, mechanics, and intercellular signalling.
The authors argue that waiting for cells or tissues to age naturally in culture is impractical, so accelerated or synthetic ageing methods are needed. They propose several routes:
- Using aged donor cells or tissues directly, including aged ECM.
- Artificially ageing young or hiPSC-derived cells, for example through oxidative stress, inflammatory stimuli, UV/carcinogen exposure, mitochondrial dysfunction, telomere attrition, CRISPR-based gene editing, or targeted epigenetic editing.
- Engineering aged ECM, by modifying stiffness, crosslinking, viscoelasticity, protein aggregation, collagen/fibronectin state, or using dynamic hydrogels and decellularised aged matrix.
- Manipulating organoid stem-cell niches, for example by inducing stem-cell exhaustion or changing niche support, to mimic functional ageing in complex tissues.
- Using senescent-cell cocultures and SASP factors to study how senescence drives or modulates tissue ageing.
- Exploring microgravity as a tool because spaceflight-like conditions can induce mitochondrial dysfunction and ageing-like phenotypes.
The figures are mainly conceptual. Figure 1 on page 2 shows young cells, adult stem cells, and hiPSCs being driven toward aged phenotypes by cellular and extracellular factors, then used for ageing-on-chip, disease modelling, biomarker discovery, gerotherapeutic/senolytic screening, and age-specific pharmacotoxicology. Figure 2 on page 3 separates the engineering task into two arms: aged cells and aged ECM, each obtainable biologically or synthetically.
The paper concludes that ageneered models could help create more realistic in vitro systems for late-onset diseases, personalised pharmacology, biomarker discovery, gerotherapeutic screening, and testing age-dependent drug toxicity. It also stresses the need for standardised biomarkers and benchmarking against genuinely aged human tissues and ECM.
Novelty
The main novelty is not a new experimental result, but a framing and agenda-setting proposal. The authors give a name — ageneering — to the deliberate engineering of biological age in cells, matrices, and microtissues.
The useful conceptual novelty is that they treat ageing as an engineering variable rather than as background noise. In tissue engineering, variables such as stiffness, oxygen, flow, scaffold architecture, cell type, and growth factors are routinely controlled. The authors argue that age should be controlled in the same way.
A second novel element is the explicit pairing of aged cells plus aged ECM. Many ageing models focus on cell-intrinsic senescence or epigenetic age, but this paper highlights that an aged microenvironment — stiffness, crosslinking, matrix composition, protein aggregation, and niche changes — may be just as important.
A third novelty is the translational emphasis: age-engineered tissues are presented not only as ageing models, but as tools for age-specific drug testing. This is important because drugs can have different efficacy and toxicity profiles in older tissue, yet many preclinical models are effectively young-biased.
Critique
The paper is persuasive as a short position article, but it is mostly programmatic. It sets out a research agenda rather than demonstrating that any one ageneering method produces a validated aged tissue state.
The biggest unresolved issue is what counts as “aged”. The authors acknowledge the need for standardised biomarkers, but this is the central problem. Ageing is multidimensional: epigenetic clocks, senescence markers, mitochondrial dysfunction, proteostasis, inflammatory signalling, ECM stiffening, stem-cell exhaustion, and functional decline may not move together. A model could look “old” by one marker but not another.
A second concern is that damage is not the same as ageing. ROS, UV, carcinogens, DNA damage, and mitochondrial toxins may accelerate some ageing-like phenotypes, but they can also create acute injury states that do not faithfully reproduce normal human ageing. This is especially important for pharmacotoxicology: a drug tested on a stress-damaged organoid might behave differently from one tested on chronologically aged tissue.
A third limitation is that hiPSC-derived systems are intrinsically problematic for ageing research. Reprogramming erases much of the donor’s age signature, and many organoids remain foetal-like or immature. “Re-ageing” them may therefore require both maturation and ageing, which are related but not identical processes.
A fourth issue is tissue specificity. Ageing in brain, heart, kidney, muscle, immune tissue, and vasculature has different dominant mechanisms. A generic ageneering toolbox may be useful, but validation probably needs to be tissue-by-tissue and disease-by-disease.
Finally, the paper could have gone further in proposing a validation hierarchy. A strong framework would compare ageneered tissues against: donor-aged tissue, single-cell transcriptomics, epigenetic age, proteomics, metabolomics, ECM mechanics, mitochondrial function, senescence burden, and actual tissue-level function. Without that, there is a risk of producing models that are visually or molecularly “aged-like” but not predictively useful.
Overall assessment
This is a useful conceptual paper. Its strength is in arguing that biological age should become a controllable parameter in tissue engineering, especially for organoids, organs-on-chips, geroscience, and age-specific pharmacology. Its weakness is that the field still lacks robust standards for distinguishing authentic ageing from artificial stress, injury, senescence overload, or incomplete maturation. The proposal is valuable, but the hard work will be in validation.